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Everolimus – an inhibitor of the mTOR 
pathway – has an established role in the 
treatment of advanced renal cell cancer 
(RCC), neuroendocrine tumors of pan-
creatic origin (pNET) and renal angiomy-
olipoma and tuberous sclerosis complex 
(TSC) [1]. Moreover, everolimus, combined 
with the aromatase inhibitor exemestane, 
has been approved for the treatment of 
postmenopausal patients with advanced 
breast cancer positive for the hormone 
receptors (HR+) and negative for the 
HER2- recurring or progressing after treat-
ment with nonsteroidal aromatase inhibi-
tors [2]. Everolimus is administered orally, 
at a dose of 10 mg/day continuously. At this 
dosage, no evidence of cumulative toxicity 
has been reported in clinical trials over a 
period of 20–52 weeks [2]. The optimal use 
of everolimus in breast cancer relies upon 
adequate management, in order to maxi-
mize treatment exposure and, therefore, 
optimize the clinical outcomes. However, 
since everolimus has only recently entered 
the breast cancer arena, physicians may 
be unfamiliar with its adverse event pro-
file and their management. Given the 
low threshold for change in therapy in 
the breast cancer setting – which can be 
likely attributed to the availability of mul-
tiple treatment options – we believe that 
information on the correct management of 
everolimus-based treatment in breast can-
cer patients is important to improve out-
comes. This editorial discusses some open 
issues related to the clinical management of 
breast cancer patients receiving everolimus.
Management of adverse events
Adverse events associated with everolimus 
might differ from those that oncologists 
endorsed to the breast cancer treatment are 
more familiar with. We comment on the 
management of some adverse events char-
acteristic of everolimus therapy, namely 
stomatitis and noninfectious pneumonitis. 
Other specific considerations on the man-
agement of specific everolimus-associated 
“The multidisciplinary management of each single breast cancer case, 
based on the involvement of several medical specialists dedicated to 
cancer treatment ... may further improve patient’s compliance to the 
administered treatment and, therefore, the management of 
everolimus-based therapy in clinical practice.”
“Everolimus – an inhibitor of the 
mTOR pathway – has an 
established role in the treatment of 
advanced renal cell cancer, 
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adverse events and other events commonly 
reported with everolimus-based therapy are 
reported elsewhere [1,3–5]. We believe that gain-
ing ‘field-practice’ experience on the manage-
ment of these adverse events might lead to better 
prevention and treatment approaches.
●● Stomatitis
Stomatitis is the most frequent event potentially 
associated with everolimus-based therapy, and 
usually occurs the first 8 weeks of treatment [4,6]. 
In the BOLERO-2 trial, the incidence of any-
grade stomatitis was 56%, while grade ≥3 
st omatitis was reported in 8% of patients [2].
Everolimus-associated stomatitis is usually 
located to the mucosa of the palate, gingiva, 
inner lips, or dorsal tongue surface. If not cor-
rectly managed, stomatitis can lead to dose 
reductions and/or therapy discontinuation, thus 
denying patients from the full benefit of everoli-
mus therapy. Therefore, proper prevention and 
early  management of stomatitis are of utmost 
importance.
Differing from stomatitis associated with 
chemotherapy or radiation therapy, stomatitis 
associated with mTOR targeted-therapy presents 
an inflammatory component with lymphocyte 
infiltrates, which often mimics aphthous sto-
matitis. In addition, mTOR-targeted therapy-
associated stomatitis differs from viral lesions as 
these latter are often located to the nonkerati-
nized movable oral and oropharynx mucosa. 
Therefore, mTOR-associated stomatitis should 
be managed with dedicated strategies [4].
Given the early onset and the potentially rele-
vant clinical sequaelae, prophylactic treatment and 
early recognition of stomatitis is highly important. 
In particular, patients should be seen 10–15 days 
since the initiation of therapy, with the aim to early 
detect the occurrence of stomatitis. Preventive and 
management measures are based on the educa-
tion of patients to oral hygiene. This should be 
based on regular brushing with a soft toothbrush, 
daily flossing, rinsing with sterile water, normal 
saline, or sodium bicarbonate; alcohol or peroxide-
containing mouthwash should be avoided. Mild, 
sodium lauryl sulfate-free toothpaste is preferred, 
whereas the use of strong-flavored toothpastes or 
those containing sodium lauryl sulfate is not rec-
ommended. At the same time, acid, spicy, hot and 
crunchy foods may be avoided. To further reduce 
the risk of mucositis, any contact of everolimus 
with oral mucosa should be avoided [4], for exam-
ple, by using cornstarch capsules to incapsulate 
everolimus in line with the ongoing experience of 
one of the authors (F Testore).
Management strategies are determined by 
symptom severity. Oral rinses with mouthwash 
solution (dexamethasone oral drops solution 
2 mg/ml, lidocaine gel 2%, sucralfate oral sus-
pension 1000 mg/5 ml, dissolved in sodium 
chloride 0.9%) may be helpful. Topical corticos-
teroids should be used as needed. Patients should 
be monitored for fungal or viral infections; 
antifungal agents should be used with caution 
because of their interaction with mTOR therapy.
●● Noninfectious pneumonitis
Pneumonitis may occur during everolimus 
therapy; however, the causative mechanisms 
underlying the association of everolimus with 
this event – if any – are not known [7]. Before 
initiating everolimus therapy, clinicians should 
evaluate pulmonary history in order to iden-
tify any pre-existing condition (i.e., pulmo-
nary fibrosis or chronic obstructive pulmonary 
 disease) r equiring pulmonary function tests.
Although some patients remain asymptomatic, 
the evaluation of symptoms (cough, dyspnea dur-
ing exertion or at rest, occasionally pleural dif-
fusion) is the first step for the identification of 
noninfectious pneumonitis in patients treated 
with everolimus. In these symptomatic patients, 
radiographic imaging by chest high resolution 
CT scan should be performed and, in some cases, 
bronchoalveolar lavage may be useful to rule out 
infection (microbiologic and virologic samples, 
alveolar cell count and alveolar lymphocytes 
phenotyping) and evaluate lung inflammation. 
Lymphocytic alveolitis without fungal or viral 
positivity strongly suggest a noninfectious pneu-
monitis associated with mTOR inhibitors [8]. 
Therapy with everolimus should be continued 
unless the symptoms become severe; in this case, 
corticosteroid treatment should be instituted in 
order to allow a fast recovery and the prosecution 
of everolimus therapy. Follow-up is performed by 
spirometry.
Everolimus dosing
Whenever possible, everolimus should be admin-
istered at full dose (10 mg/day). Dose reductions 
to 5 mg/day might be considered only in patients 
with moderate-to-severe adverse events [9].
The potential existence of an association 
between the occurrence of adverse events and effi-
cacy remains an open issue. Ravaud et al. recently 
performed a meta-analysis of clinical trials aimed 
“In everolimus-treated 
patients, a close 
cooperation of different 
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at evaluating the potential relationship between 
everolimus exposure and the safety and efficacy 
of this molecule [10]. However, in this analysis 
no patients with breast cancer were included; 
therefore, these data need to be considered with 
caution before extending them to breast cancer 
patients. The meta-analysis considered patient 
pharmacokinetic data deriving from five Phase II 
or Phase III studies. Efficacy was evaluated in a 
total of 945 patients, and safety in 938 subjects. 
The analysis showed that a twofold increase in the 
minimum concentration of everolimus is associ-
ated with an increased likelihood of reduction of 
tumor size (odds ratio: 1.4), a trend to a reduced 
risk of progression-free survival (risk ratio [RR]: 
0.9), and an increased risk of ≥grade 3 pulmonary 
toxicity (RR: 1.9), stomatitis (RR: 1.5), and meta-
bolic toxicity (RR: 1.3). Overall, these data show 
that increased exposure to everolimus is associ-
ated with both increased efficacy and a higher 
rate of high-grade toxicities, thus suggesting a 
dose-dependent antitumor effect of everolimus.
The importance of compliance
Oral administration with everolimus is associ-
ated with enhanced patients’ comfort, but also 
poses some challenges in terms of compliance. 
To our knowledge, the compliance to everolimus 
therapy in field-practice has never been addressed 
in breast cancer patients. While dedicated stud-
ies appear advocated, a German multicenter 
noninterventional study on 196 mRCC patients 
has documented high adherence (approximately 
97%) to everolimus therapy [11].
Communication with patients plays a central 
role in improving compliance. To this respect, 
breast cancer patients treated with everolimus-
based treatment should be considered as those 
undergoing chemotherapy, and should receive 
clear instructions on therapy, administration 
measures, potentially associated adverse events 
and their prevention/management at the institu-
tion of therapy. The management team should, 
if possible, remain the same over time and clini-
cians should meet each patient at least twice at the 
initiation of therapy. Patients should in particular 
be encouraged to promptly report any symptom 
experienced during therapy, in particular res-
piratory symptom such as persistent cough and 
dyspnea or the appearance of oral lesions, mouth 
pain and dysphagia. Moreover, early monitoring 
(within 2 weeks since the initiation of therapy) 
is recommended to assess the potential onset of 
stomatitis and other adverse events.
The importance of a multidisciplinary 
approach
Multidisciplinary management has mounting 
importance in breast cancer. In fact, optimal 
patient care and outcomes depend on the par-
ticipation and dialogue between specialists in 
imaging, pathologic and molecular diagnostic, 
surgery, radiation oncology, and medical oncol-
ogy [12]. In everolimus-treated patients, a close 
cooperation of different specialists is crucial 
to optimize clinical outcomes. For instance, 
dentists and oral cavity specialists may allow a 
better management of stomatitis. If the patient 
presents with respiratory symptoms, a radiolo-
gist and pulmonologist consultation is recom-
mended to detect early radiological signs of 
noninfectious pneumonitis and to facilitate 
differential diagnosis. In addition, nurses may 
educate patients on potential adverse events and 
their prevention and management [13].
Conclusion
Everolimus represents a relatively new therapy in 
the complex treatment scenario of breast cancer. 
In order to prolong treatment duration, to avoid 
dose discontinuations and, therefore, maximize 
the clinical benefit and outcomes, an early moni-
toring for the potential onset of adverse events 
should be instituted; at the same time, patients 
should be educated to report any symptoms 
experienced during therapy and to apply some 
preventive measures.
The multidisciplinary management of each 
single breast cancer case, based on the involve-
ment of several medical specialists dedicated to 
cancer treatment, together with the continuous 
communication with breast cancer patients, 
may further improve patient’s compliance to 
the administered treatment and, therefore, the 
management of everolimus-based therapy in 
clinical practice.
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